Stocktoria
IRONWOOD PHARMACEUTICALS INC IRWD
IRONWOOD PHARMACEUTICALS INC (IRWD) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $296.2M at a 8.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.081 |
| Retained earnings / assets | -4.217 |
| EBIT / assets | 0.248 |
| Equity / liabilities | -0.397 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IRWD | IRONWOOD PHARMACEUTICALS INC | 4/9 | -11.97 | 28.3 | -15.7% |
| EOLS | Evolus, Inc. | 2/9 | -8.65 | — | +11.6% |
| RIGL | RIGEL PHARMACEUTICALS INC | 5/9 | 0.31 | 2 | +64.1% |
| XERS | Xeris Biopharma Holdings, Inc. | 7/9 | -2.99 | — | +43.7% |
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
| CRMD | CorMedix Inc. | 5/9 | 3.07 | 3.8 | +617% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
About IRONWOOD PHARMACEUTICALS INC
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
FAQ
Is IRWD financially healthy?
IRONWOOD PHARMACEUTICALS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IRWD pay a dividend?
No, IRONWOOD PHARMACEUTICALS INC does not currently pay a dividend.
How profitable is IRWD?
In FY2025, IRONWOOD PHARMACEUTICALS INC had a net margin of 8.1%.
Is IRWD overvalued or undervalued?
IRONWOOD PHARMACEUTICALS INC trades at about 28.8× trailing earnings — below its 10-year norm (10-year range 3.5×–234.0×, median 32.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for IRWD?
The average Wall-Street price target for IRONWOOD PHARMACEUTICALS INC is $6.10, about 41.2% above the recent price, from 4 analysts.
Is IRWD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IRONWOOD PHARMACEUTICALS INC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 28.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.